CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

The goal of this clinical trial is to learn whether 89Zr-Girentuximab PET scans can inform management of renal cell carcinoma. The main questions it aims to answer are: * Does the 89Zr-Girentuximab PET detect ccRCC that is left behind or has come back after treatment? * What differences can be seen on the 89Zr-Girentuximab PET before and after standard of care treatment? Participants in arm 1 will be given the study drug followed by a PET scan 3-7 days after injection. Participants in arm 2 will receive the same, but will proceed with their standard of care cryoablation after the initial PET scan. Within 3 days of the cryoablation treatment, participants will receive a repeat PET scan.

NCT Number	NCT07077083
Lead Sponsor	Massachusetts General Hospital Collaborators: Telix Pharmaceuticals (Innovations) Pty Ltd
Conditions	Clear Cell Renal Cell Carcinoma (ccRCC), ccRCC
Enrollment	10 participants
Start Date	2026-09-16
Primary Completion	2027-08-01 (estimated)
Study Completion	2028-08-01 (estimated)
Updated on ClinicalTrials.gov	2026-07-21